Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 3/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.32 |
| ▸ | USP14 | P54578 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9299143 | 0.85 | GPR84 (0.43) | DUTNSD2ABL1PPARGRIN1 | |
| SCHEMBL9300372 | 0.82 | DUT (0.47) | DUTNSD2ABL1PPARGRIN1 | |
| SCHEMBL9300254 | 0.76 | DUT (0.40) | DUTCGASUSP14PREPBACE1 | |
| SCHEMBL2076432 | 0.76 | AHR (0.41) | ABL1 | |
| SCHEMBL1607218 | 0.76 | MEN1 (0.41) | ABL1BACE1HPGD | |
| SCHEMBL20648641 | 0.72 | TYK2 (0.37) | — | |
| SCHEMBL31139306 | 0.71 | IDO1 (0.36) | BACE1 | |
| SCHEMBL4976106 | 0.71 | IDO1 (0.36) | BACE1 | |
| SCHEMBL12391764 | 0.71 | NSD2 (0.39) | NSD2ABL1PPARGRIN1L3MBTL1 | |
| SCHEMBL3350182 | 0.71 | KDR (0.52) | ABL1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED | 2011-05-19 | — | — | US | disclosed |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | GLAXO GROUP LIMITED | 2011-05-19 | — | — | US | disclosed |
| US-20030220241-A1 | Method of treating cancer | DEFEO-JONES DEBORAH (US) | 2003-11-27 | — | — | US | disclosed |
| WO-2000059930-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| US-6093737-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 2000-07-25 | — | — | US | disclosed |
| EP-1003374-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1003374-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-2000016778-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-1998028980-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1998-07-09 | — | — | WO | disclosed |
| US-5296492-A | Certain chroman derivatives useful for treating symptoms caused by contraction of smooth muscles, circulatory diseases or epilepsy | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1994-03-22 | — | — | US | disclosed |
| EP-0518342-A1 | Chroman derivatives | Nippon Kayaku Kabushiki Kaisha (JP) | 1992-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220241-A1 | Method of treating cancer | ACP3, PSAT1, LCAT | DUT 30/4885NSD2 2748/4885ABL1 776/4885 |
| US-20110118261-A1 | BIS-PYRIDYLPYRIDONES AS MELANIN-CONCENTRATING HORMONE RECEPTOR 1 ANTAGONISTS | MCHR1, MCHR2, MC1R | DUT 4726/4885NSD2 3848/4885ABL1 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.